Clinical correlation between serum pepsinogen level and gastric atrophy in gastric neoplasm
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: The relationship between the serum pepsinogen (sPG) level and changes in gastric mucosa has been well studied. Here, we evaluated the usefulness of sPG (I, II, I/II ratio) and intragastric pH as a biomarker of severe gastric atrophy in gastric neoplastic lesions. Methods: A total of 186 consecutive Korean patients with gastric neoplastic lesions underwent endoscopic submucosal dissection (ESD) in this study. The serologic atrophy group had sPG I level ≤ 70 ng/mL and an sPG I/II ratio ≤ 3.0. Before ESD, overnight fasting venous blood and gastric juice samples were collected to measure the sPG level and intragastric pH. The degree of gastric atrophy was estimated by endoscopy, and the rapid urease test was performed to investigate Helicobacter pylori infection. Results: Patients who met the criteria of serologic atrophy showed more severe endoscopic atrophic changes (61% vs. 18%, p = 0.000). Older patients and those with more atrophic changes at the gastric upper body demonstrated both a lower sPG I level and a lower PG I/II ratio and more severe endoscopic atrophy. The sPG I/II ratio was the lowest in low grade dysplasia than in high grade dysplasia and early gastric cancer (EGC) (p = 0.015). In addition, patients who tested negative for serologic atrophy and H. pylori showed the lowest intragastric pH (p = 0.000). Conclusions: A low sPG I level and a low I/II ratio were correlated with the severity of gastric atrophy in gastric neoplastic lesions, thus indicating it to be a sensitive biomarker of gastric precancerous lesions or EGC.
Abstract
Background/Aims: The relationship between the serum pepsinogen (sPG) level and changes in gastric mucosa has been well studied. Here, we evaluated the usefulness of sPG (I, II, I/II ratio) and intragastric pH as a biomarker of severe gastric atrophy in gastric neoplastic lesions. Methods: A total of 186 consecutive Korean patients with gastric neoplastic lesions underwent endoscopic submucosal dissection (ESD) in this study. The serologic atrophy group had sPG I level ≤ 70 ng/mL and an sPG I/II ratio ≤ 3.0. Before ESD, overnight fasting venous blood and gastric juice samples were collected to measure the sPG level and intragastric pH. The degree of gastric atrophy was estimated by endoscopy, and the rapid urease test was performed to investigate Helicobacter pylori infection. Results: Patients who met the criteria of serologic atrophy showed more severe endoscopic atrophic changes (61% vs. 18%, p = 0.000). Older patients and those with more atrophic changes at the gastric upper body demonstrated both a lower sPG I level and a lower PG I/II ratio and more severe endoscopic atrophy. The sPG I/II ratio was the lowest in low grade dysplasia than in high grade dysplasia and early gastric cancer (EGC) (p = 0.015). In addition, patients who tested negative for serologic atrophy and H. pylori showed the lowest intragastric pH (p = 0.000). Conclusions: A low sPG I level and a low I/II ratio were correlated with the severity of gastric atrophy in gastric neoplastic lesions, thus indicating it to be a sensitive biomarker of gastric precancerous lesions or EGC.
참고문헌 (31)
- Oksanen A, "Evaluation of blood tests to predict normal gastric mucosa", Scand J Gastroenterol, 35, pp.791~795 (2000)
- Korstanje A, "The serological gastric biopsy: a non-endoscopical diagnostic approach in management of the dyspeptic patient: significance for primary care based on a survey of the literature", Scand J Gastroenterol Suppl, 236, pp.22~26 (2002)
- Foltmann B, "Gastric proteinases : structure, function, evolution and mechanism of action", Essays Biochem, 17, pp.52~84 (1981)
- Samloff IM, "Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology : a study in relatives of patients with pernicious anemia", Gastroenterology, 83(1 Pt 2), pp.204~209 (1982)
- Borch K, "The ratio of pepsinogen A to pepsinogen C : a sensitive test for atrophic gastritis", Scand J Gastroenterol, 24, pp.870~876 (1989)
- Vaananen H, "Non-endoscopic diagnosis of atrophic gastritis with a blood test:correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study", Eur J Gastroenterol Hepatol, 15, pp.885~891 (2003)
- Samloff IM, "A study of the relationship between serum group I pepsinogen levels and gastric acid secretion", Gastroenterology, 69, pp.1196~1200 (1975)
- Feldman M, "Comparison of gastric acid secretion rates and serum pepsinogen I and II concentrations in occidental and oriental duodenal ulcer patients", Gastroenterology, 95, pp.630~635 (1988)
- Miki K, "Serum pepsinogens as a screening test of extensive chronic gastritis", Gastroenterol Jpn, 22, pp.133~141 (1987)
- Iijima K, "Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach", World J Gastroenterol, 15, pp.853~859 (2009)
- Miki K, "Gastric cancer screening using the serum pepsinogen test method", Gastric Cancer, 9, pp.245~253 (2006)
- Kitahara F, "Accuracy of screening for gastric cancer using serum pepsinogen concentrations", Gut, 44, pp.693~697 (1999)
- Ruiz B, "Antral atrophy, Helicobacter pylori colonization, and gastric pH", Am J Clin Pathol, 105, pp.96~101 (1996)
- Jaskiewicz K, "Chronic atrophic gastritis, gastric pH, nitrites and micronutrient levels in a population at risk for gastric carcinoma", Anticancer Res, 10, pp.833~836 (1990)
- Yim JY, "Seroprevalence of Helicobacter pylori in South Korea", Helicobacter, 12, pp.333~340 (2007)
- Kang JM, "The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea", Helicobacter, 13, pp.146~156 (2008)
- 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2011", Cancer Research and Treatment, 43(1), pp.12~18 (2011), 대한암학회
- Namekata T, "Chronic atrophic gastritis and Helicobacter pylori infection among Japanese Americans in Seattle", Am J Epidemiol, 151, pp.820~830 (2000)
- Sipponen P, "Gastric cancer risk in chronic atrophic gastritis : statistical calculations of cross-sectional data", Int J Cancer, 35, pp.173~177 (1985)
- Yamada S, "Helicobacter pylori infection in combination with the serum pepsinogen I", II ratio and interleukin-1beta-511 polymorphisms are independent risk factors for gastric cancer in Thais, 2006, pp.41, 1169~1177
- Sitas F, "Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis", Cancer Epidemiol Biomarkers Prev, 2, pp.119~123 (1993)
- Yoshihara M, "Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects", Am J Gastroenterol, 93, pp.1090~1096 (1998)
- Hattori Y, "Sensitivity and specificity of mass screening for gastric cancer using the measurement of serum pepsinogens", Jpn J Cancer Res, 86, pp.1210~1215 (1995)
- Dinis-Ribeiro M, "Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening", J Med Screen, 11, pp.141~147 (2004)
- Yoo JY, "Detection rate of Helicobacter pylori against a background of atrophic gastritis and", or intestinal metaplasia, 2007, pp.41, 751~755
- Shin CM, "Validation of diagnostic tests for Helicobacter pylori with regard to grade of atrophic gastritis and", or intestinal metaplasia, 2009, pp.14, 512~519
- Weck MN, "Helicobacter pylori infection and chronic atrophic gastritis : associations according to severity of disease", Epidemiology, 20, pp.569~574 (2009)
- Kikuchi S, "Long-term effect of Helicobacter pylori infection on serum pepsinogens", Jpn J Cancer Res, 91, pp.471~476 (2000)
- Ito M, "Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia : a 5-year prospective study of patients with atrophic gastritis", Aliment Pharmacol Ther, 16, pp.1449~1456 (2002)
- Lorente S, "Helicobacter pylori stimulates pepsinogen secretion from isolated human peptic cells", Gut, 50, pp.13~18 (2002)
- Chang YW, "Clinical parameters including serum pepsinogen level and management strategy in patients with premalignant gastric dysplasia", Eur J Gastroenterol Hepatol, 23, pp.405~410 (2011)